摘要
目的观察雷珠单抗玻璃体腔注射联合Ahmed青光眼阀(AGV)植入及全视网膜光凝(PRP)治疗新生血管性青光眼(NVG)的临床疗效。方法回顾分析我院2016年6月至2017年6月间收治的16例(16只眼)NVG病例的临床资料,所有病例治疗上均先行玻璃体腔雷珠单抗注射,注射后5~7 d行Ahmed青光眼阀植入,术后1周门诊行PRP。观察治疗前后虹膜新生血管改变情况以及眼压变化情况。结果 16例患者虹膜新生血管注射雷珠单抗后全部或部分消退,Ahmed青光眼阀植入均顺利进行,未出现术中前房出血等并发症,术后未出现不可控并发症。随访至术后3个月,所有患者术后眼压较术前均显著降低,差异有统计学意义(P<0.05)。结论雷珠单抗玻璃体腔注射联合Ahmed青光眼阀植入及PRP治疗NVG疗效显著。
Objective To investigate the effects of intravitreal injection of ranibizumab combined with Ahmed glaucoma valve(AGV)implantation and panretinal photocoagulation(PRP)for the treatment of neovascular glaucoma(NVG).Methods A retrospective analysis of 16 cases(16 eyes)of neovascular glaucoma in our hospital between June 2016 and June 2017.Patients were intravitreally injected with Lucentis 5~7 d prior to surgery for Ahmed valve implantation,and PRP was given a week after surgery.All patients were observed before and after treatment for iris neovascularization and intraocular pressure.Results Iris neovascularization partially or completely subsided in all patients after ranibizumab injection.Ahmed glaucoma valve implantation was performed successfully without complications.Up to 90 days after treatment,the IOP was significantly decreased in all patients and the difference was statistically significant(P<0.05).Conclusions Intravitreal injection of ranibizumab combined with Ahmed glaucoma valve implantation and panretinal photocoagulation for neovascular glaucoma is effective.
作者
李鑫
陈毕锋
胡庆华
叶应嘉
杨兰
Li Xin;Chen Bifeng;Hu Qinghua;Ye Yingjia;Yang Lan(Wuhan Hanyyang Aier Eye Hospital,Hubei 430000,China)
出处
《临床眼科杂志》
2018年第3期221-223,共3页
Journal of Clinical Ophthalmology
作者简介
通讯作者:李鑫(Email:lixin427@qq.com)。
